866-997-4948(US-Canada Toll Free)

Hyperglycemia - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Apr 2014

Category :

Metabolic Disorders

No. of Pages : 38 Pages

Hyperglycemia Pipeline Review, H1 2014, provides an overview of the Hyperglycemias therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hyperglycemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperglycemia and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hyperglycemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Hyperglycemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Hyperglycemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hyperglycemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hyperglycemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hyperglycemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hyperglycemia Overview 6
Therapeutics Development 7
Pipeline Products for Hyperglycemia - Overview 7
Pipeline Products for Hyperglycemia - Comparative Analysis 8
Hyperglycemia - Therapeutics under Development by Companies 9
Hyperglycemia - Therapeutics under Investigation by Universities/Institutes 10
Hyperglycemia - Pipeline Products Glance 11
Early Stage Products 11
Hyperglycemia - Products under Development by Companies 12
Hyperglycemia - Products under Investigation by Universities/Institutes 13
Hyperglycemia - Companies Involved in Therapeutics Development 14
Kissei Pharmaceutical Co., Ltd. 14
Mitsubishi Tanabe Pharma Corporation 15
PhaseBio Pharmaceuticals, Inc. 16
Hyperglycemia - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 23
Drug Profiles 25
Insumera - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Small Molecules to Inhibit SGLT1 for Postprandial Hyperglycemia - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
KR-62980 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ZLN-005 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecules to Inhibit PEPCK for Diabetes and Hyperglycemia - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
55-P-0251 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
latanoprost - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecule to Inhibit DPP-IV for Hyperglycemia - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
FGH-10019 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Hyperglycemia - Dormant Projects 34
Hyperglycemia - Product Development Milestones 35
Featured News & Press Releases 35
Dec 06, 2011: Study Shows Combination Insulin Degludec/Insulin Aspart Significantly Reduced Hypoglycaemia In Type 1 And Type 2 Diabetes Patients 35
Nov 15, 2011: PhaseBio Announces Positive Results From Phase I/IIa Trial Of Glymera For Treatment Of Hyperglycemia In Patients With Type 2 Diabetes 35
Jul 21, 2011: Kissei Pharma Launches Glubes In Japan For Treatment Of Type 2 Diabetes 36

Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38

List of Table


Number of Products under Development for Hyperglycemia, H1 2014 7
Number of Products under Development for Hyperglycemia - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Early Stage Development, H1 2014 11
Products under Development by Companies, H1 2014 12
Products under Investigation by Universities/Institutes, H1 2014 13
Hyperglycemia - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2014 14
Hyperglycemia - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014 15
Hyperglycemia - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2014 16
Assessment by Monotherapy Products, H1 2014 17
Number of Products by Stage and Target, H1 2014 19
Number of Products by Stage and Mechanism of Action, H1 2014 21
Number of Products by Stage and Route of Administration, H1 2014 22
Number of Products by Stage and Molecule Type, H1 2014 24
Hyperglycemia - Dormant Projects, H1 2014 34

List of Chart


Number of Products under Development for Hyperglycemia, H1 2014 7
Number of Products under Development for Hyperglycemia - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 11
Assessment by Monotherapy Products, H1 2014 17
Number of Products by Top 10 Target, H1 2014 18
Number of Products by Stage and Top 10 Target, H1 2014 19
Number of Products by Top 10 Mechanism of Action, H1 2014 20
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 21
Number of Products by Top 10 Molecule Type, H1 2014 23
Number of Products by Stage and Top 10 Molecule Type, H1 2014 24

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *